Unilife is a U.S. based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for our products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. All of our syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. We are ISO 13485 certified and have FDA-registered medical device manufacturing facilities in Pennsylvania.
Our main product is the UnifillTM ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with their injectable drugs and vaccines. We have a strategic partnership with sanofi-aventis, who has the exclusive right to negotiate for the purchase of the Unifill syringe and is funding our industrialization program. In addition, we have retained the right to negotiate with other pharmaceutical companies seeking to utilize the Unifill syringe with drugs and vaccines marketed in therapeutic areas outside of those secured exclusively by sanofi-aventis.
News & Events
Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), today announced that its Chairman and CEO, Alan Shortall will present at the Leerink Swann Global Healthcare Conference in New York at 1:50 p.m. EST on Thursday, February 13, 2014 (Friday, February 14th at 5:50 a.m. AEDT). The event, which is in a fireside
Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) announced today that it intends to release its financial results for the fiscal 2014 second quarter ended December 31, 2013 after market trading ends on Monday, February 3, 2014. Management has scheduled a conference call for 4:30 p.m. U.S. EST on Monday,
Unilife announced the signing of an agreement with a pharmaceutical company seeking to use the Unilife Ocu-ject ocular drug delivery system to deliver a target injectable therapy into the eye. The identity of the pharmaceutical company, as well as other terms of the agreement, are not disclosed for commercial purposes and due to
Unilife ($UNIS) is at it again. This time it's Novartis ($NVS) signing a deal with the injectable technology provider, adding to Unilife's impressive list of recent agreements with top pharmaceutical companies Sanofi ($SNY), MedImmune and Hikma. Unilife and Novartis are keeping details of the deal under wraps for the most pa